Answers are grounded in this paper and cite their sources.
The analysis included 466 patients with myelofibrosis on treatment with ruxolitinib. The PFS at 12 th , 20 th , 30 th , 40 th , and 50 th month was 88%, 83%, 75%, 65%, and 61% respectively. Median for PFS was reached at 73.5 months. OS median was reached at 48.2 months. OS at month 12 th , 20 th , 30 th , and 40 th month was 87%, 78%, 70%, and 56% respectively. Eligible patients for comparison with COMFORT-II trial after application of inclusion and exclusion criteria were 68, while the clinical trial included 146 patients. The estimated value for PFS at 12 th month was 84% and the median PFS was reached at 35.3 months. The values for OS was estimated to be 74% at 12 th month and the median of OS was reached at 30 th month. The clinical benefit rate from real-world population was estimated at 98%, and objective response rate was estimated at 79.2%, based on 53 patients.
No takes yet. Share an insight, caveat, or question.
Rangelov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: